Navigation Links
HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services
Date:12/3/2008

COLORADO SPRINGS, Colo. and REYKJAVIK, Iceland, Dec. 3 /PRNewswire/ -- HemoGenix(R) and ORF Genetics announce the collaboration and implementation of biorisk-free, green-source growth factors and cytokines for use in all HALO(R) Assay Kits and HALO(R) Contract Research Services where the response of human blood-forming cells is detected.

ORF Genetics produces a large number of growth factors and cytokines using barley seed as the production host. Their Orfeus(TM) Expression System, comprised of a barley endosperm expression background, gf22 expression cassette, HEKLAgro(TM) cultivation technology, and the production of isogenic lines for seed banking, makes this the most efficient and "green" production of human growth factors and cytokines for R&D medical research, cellular therapy, regenerative medicine, cosmetics and biopharma. ORF Genetics products are free of contaminants for bacterial, viral and prion components; non- pyrogenic; endotoxin-free; and perfectly safe according to FDA guidelines.

Through close collaboration, HemoGenix(R) has tested the growth factors and cytokines produced by ORF Genetics and found them to produce similar, if not superior, potency for growth of human bone marrow, cord blood and peripheral blood cells using its HALO(R) ATP-based, bioluminescence proliferation/cytotoxicity assay platform. The growth factors and cytokines needed to stimulate and detect various blood-forming stem and progenitor cell populations will now be incorporated into the complete line of HALO(R) Assay Kits produced by HemoGenix(R). This is particularly important for the family of HALO(R) quality control and potency assays used to ensure "stem cell quality" and "stem cell potency" for release of stem cell products, particularly umbilical cord blood, prior to transplantation into patients.

HemoGenix(R) will also incorporate ORF Genetics growth factors and cytokines into its HALO(R) Hemotoxicity Assay Kits and for its Contract Research Services using the HALO(R) Platform.

Ivan Rich, PhD, Founder and CEO of HemoGenix(R), said that, "It has been a pleasure working with ORF. Their response and products have been exceptional. Incorporating these growth factors and cytokines in our HALO(R) Platform products is extremely important for our quality control and potency assays, because we can now use biorisk- and contaminant-free products that provide far greater clinical relevance for the results that are obtained with our kits and services."

Bjorn Orvar, PhD, Co-founder and CEO of ORF Genetics, said that, "ORF Genetics ISOkine(TM) growth factors produced in our Orfeus(TM) plant-based production system are not only a novel approach for producing growth factors, but also a much-needed option for endotoxin-free, and animal- and serum-free components, for cell culture and medical research. HemoGenix(R) is a global leader of developing kits and assays for high throughput and validated cell- based assays for the detection and prediction of hemotoxicity, and we are very pleased to collaborate with HemoGenix(R) for the incorporation of our ISOkine(TM) growth factors and cytokines in its HALO(R) Hemotoxicity Assay Kits and Contract Research Services using the HALO(R) platform."

About HemoGenix(R), Inc

HemoGenix(R) was the first company in the world to provide high throughput and predictive cell-based in vitro assays to detect human hemotoxicity (toxicity to the blood-forming system). The HALO(R) Platform and other proprietary assays (LUMENESC(TM) and LumiSTEM(TM)) for different cell systems share the same ATP-based, in vitro bioluminescence technology. This allows biological responses to virtually any agent to be directly compared with each other across cell systems from different species simultaneously. Since its founding in 2000, HemoGenix(R) has developed its own portfolio of patented assays for basic research, toxicity, safety and risk assessment for the biopharmaceutical and environmental arenas, and quality control and potency assays for stem cell transplantation processing laboratories. HemoGenix(R) produces and sells its assays directly or through its distributors worldwide. HemoGenix(R) is a privately owned company.

About ORF Genetics, hf.

ORF Genetics was the first company to introduce biorisk-free growth factors to global R&D. Headquartered in Reykjavik, Iceland, ORF Genetics, hf. is a privately owned biotech company that is committed to economically viable, green technology for the production of growth factors and hard to produce recombinant proteins. Utilizing its unique Orfeus(TM) plant-based expression system, the company is currently the only provider of such growth factors to serve the needs of the medical research, cell culture media, diagnostics and cosmetic markets. ORF was recently awarded the prestigious 2008 Icelandic Innovation Award by the Icelandic Center for Research and the Icelandic Trade Council. The annual award is given to a single Icelandic company that is pioneering research and development.

    CONTACT:
    Ivan N. Rich, PhD
    Founder and CEO
    719-264-6250
    ivannr@hemogenix.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE HemoGenix, Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
2. Decision Biomarkers Inc Announces Formation of Scientific Advisory Board
3. Enigma Diagnostics Announces the Opening of a United States Office
4. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
5. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
6. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
7. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
8. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
9. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
10. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
11. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading ... the Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio ... and clinical trial team. , Using the CONSULT module, patients and physicians can schedule ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
Breaking Biology Technology:
(Date:6/22/2016)... -- On Monday, the Department of Homeland Security (DHS) ... for the Biometric Exit Program. The Request for Information ... explains that CBP intends to add biometrics to confirm ... States , in order to deter visa overstays, ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):